Agreed with kelt and Ms Seel. All is well, but the silence

New Post Public Reply Private Reply Replies (0) Message Board
TheProgressive seel #9490
Agreed with kelt and Ms Seel. All is well, but the silence is deafening. Perhaps Leo is just slammed with work (most likely), but perhaps he is on to something big. You make a good point kelt. What would cause him not to show in front of all that big money at IDEAS? I am excited about the possibilities. Big oharma has been watching this drug closely for years. They know exactly what its capable of. They know the trial is 7 months in and full speed ahead (although admittedly slower than us crazy shareholders would prefer).

They also know that so far, so good on the safety side. That is huge in itself. We often lose sight of that, because as investors, IMO we have lost perspective on how much we are getting out of his P1 trial. Safety in itself is a huge win, as it lays the solid foundation and groundwork for all other combination trials to hit the ground running hard once MTD is established at Dana Farber. We are building a CTIX mansion, and right now Dana Farber is pouring the foundation and waiting for the concrete (data) to harden.

Who's to say that Pfizer, the big kid on the block, or Celgene, the dark horse candidate, haven't already seen enough from a safety standpoint to dip their feet in the water? Think about it, say they even agree to do a very basic JV to help fund and expand trials, say they drop 500 million (just a random WAG number) to make it happen in some way, shape, or form. Just something to lay the groundwork with Leo to give them a leg up on possibly owning the drug down the road. Celgene or Pfizer taking a 500 million dollar gamble on Kevetrin is like one of us deciding to take a 5 dollar gamble on the powerball. If we dont win, who cares? Won't even make a dent in our bottom line. Im sure big pharma feels the same and that is why i believe there may be some type of "entry level" JV in the works, hence the silence from the CEO. Just IMO of course, it very well could be as simple as Leo is working 12-14 hours a day to run a company that has a hell of a lot going for it.

But I don't believe that, I think great things are coming, and soon after DF gets to share their good work with the world.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

BrainsWay Achieves Record Revenue and Strategic Growth in 2025

Updated Category News Views 256

Exploring BrainsWay's Remarkable Q2 Results BrainsWay Ltd. (NASDAQ: BWAY), a prominent player in neurostimulation treatments for mental health disorders, recently announced its extraordinary financial performance for the second quarter of 2025. The company achieved a record quarterly revenue of $12.6 million, marking a notable 26% increase compared to the same quarter in...

Continue Reading
CDC Foundation Pushes for Urgent Ebola Response

Updated Category News Views 33

Sounding the Alarm on Ebola In a world where crises come and go like the seasons, the latest Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda ought to command our undivided attention. We've seen this movie before, yet here we are with an Ebola variant—Bundibugyo this time—that threatens to spiral out of control. The CDC Foundation has sounded...

Continue Reading
Apple Faces Class Action Over Alleged AI Misrepresentation

Updated Category News Views 279

Apple's Legal Challenges: Class Action Lawsuit Over AI Features Pomerantz LLP has announced the initiation of a class action lawsuit against Apple Inc. (NASDAQ: AAPL) and select executives, focusing on claims surrounding the company’s advertised artificial intelligence capabilities. This legal action stems from allegations of misleading information disseminated to...

Continue Reading
Celebrate Togetherness with Aperol's Inaugural Aperolidays

Updated Category News Views 240

Introducing Aperolidays: A Celebration of Togetherness Aperol, the beloved Italian aperitivo, is stepping into the holiday spirit by announcing the inaugural Aperolidays. This unique celebration aims to infuse joy and connection into the winter season, inviting everyone to gather and enjoy the quintessential Italian way of life. New Festive Merchandise and Experiences...

Continue Reading
Acorai Unveils Breakthroughs in Heart Failure Monitoring Solutions

Updated Category News Views 233

Acorai's Impactful Results in Heart Failure Management Acorai, a clinical-stage company focused on innovative ways to manage heart failure, recently shared impressive findings from the extensive 1,600-patient CAPTURE-HF study. The study focused on a novel, non-invasive multi-sensor device aimed at improving the way healthcare professionals monitor heart failure patients....

Continue Reading